EUCTR2008-005972-29-HU进行中（未招募）不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria are: male or female subject who:
- •1. has a diagnosis of STE-ACS, NSTE-ACS as index event according to accepted guidelines such as the ESC or AHA guideline,
- •2. has elevated cardiac biomarkers (cardiac Troponin T or I or CKMB) 2x ULN for CK-MB or > ULN for troponin,
- •3. has at least one of the following additional high risk factors for ischemic events:
- •New ST-T deviations on Electrocardiogram (ECG)
- •Age of 65 years or older
- •Previous ACS < 12 months prior to randomization
- •Multi vessel Coronary Artery Disease (CAD)
- •Ischemic stroke or Transient Ischemic Attack (TIA) >12 months prior to randomization
- •Type 2 Diabetes Mellitus
- •Peripheral Arterial Disease (PAD),
- •4. is clinically stable which is defined as discontinuation of parenteral antithrombotics and is not likely to require reinstallment of parenteral antithrombotics at time of randomization and receives current standard oral antiplatelet therapy,
- •5. is able to be randomized within 7 days after presentation with STE-ACS or NSTE-ACS following management to current best clinical practice in the study centre. This may include thrombolysis or primary Percutaneous Coronary intervention (PCI) for STE-ACS, or early invasive strategy (including PCI) for non-STE-ACS subjects. Subjects should be randomized as soon as possible after discontinuation of parenteral antithrombotics,
- •6. has provided Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations or Informed Consent has been obtained from the legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable),
- •7. is 18 years of age (legal minimum age required per country) or older at time of informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria at time of randomization: subject
- •1. requires ongoing parenteral or oral anticoagulant therapy (such as vitamin K antagonists, Unfractionated Heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, thrombin inhibitors), thrombolytics (such as Tissue Plasminogen Activator (TPA), streptokinase), Glycoprotein (GP) IIb/IIIa antagonists or other antiplatelet drugs (such as cilostazol, ticlopidine, dipyridamole, prasugrel),
- •2. is planned for myocardial revascularization (e.g., Coronary Artery Bypass Graft (CABG) or elective or staged PCI) or any other invasive procedure with increased risk for bleeding (i.e. elective surgical procedures) within 60 days after randomization,
- •3. has active bleeding or is in the opinion of the investigator at high risk of bleeding during the study,
- •4. has had recent stroke or TIA = 12 months prior to index event,
- •5. has a bleeding diathesis or any other condition or laboratory abnormality with an increased tendency for bleeding (e.g., platelet count below 100.000/uL),
- •6. is a female of childbearing potential who refuses to use a medically acceptable form of contraception throughout the study. Acceptable methods of contraception include the following: oral or injectable hormonal contraceptives, intrauterine devices, vaginal hormonal rings, and only in combination with a male condom, a vaginal diaphragm or cervical caps. Male study subjects should be advised to use male condom in addition to having their partner use another acceptable method during the study and for three months after the last dose,
- •7. is a female who is pregnant or lactating or has a positive pregnancy test within 72 hours prior to randomization;
- •8. has persistent blood pressure of 160 mmHg systolic or higher and/or 100 mmHg diastolic or higher at baseline with or without medication,
- •9. has hepatic insufficiency or presents with ALT > 2.0 times the ULN or total bilirubin > 1.5 times the ULN (result based on (local) laboratory testing on blood sample drawn within maximally 24 hours prior to randomization),
- •10. has a estimated renal creatinine clearance of <60 mL/min as calculated by the Cockcroft-Gault equation (result based on (local) laboratory testing on blood sample drawn maximally 24 hours prior to randomization),
- •11. has any concurrent illness which, in the opinion of the investigator, may interfere with treatment or evaluation of safety or completion of this study,
- •12. has participated in another clinical trial of an investigational drug (including placebo) or device within 30 days (or the limit set by national law, whichever is longer) of signing informed consent for the present study,
- •13. has participated in any YM150 clinical trials,
- •14. has known allergy to the study drug or any of its components.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyThe investigation will be carried out on subjects with Acute Coronary Syndromes.MedDRA version: 12.0Level: LLTClassification code 10049166Term: Coronary artery thrombosis prophylaxisEUCTR2008-005972-29-FRAstellas Pharma Europe B.V.1,264
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyEUCTR2008-005972-29-LVAstellas Pharma Europe B.V.1,264
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients - NDCMV disease in high risk kidney transplant recipientsMedDRA version: 6.1Level: PTClassification code 10011831EUCTR2005-002817-19-ITROCHE316
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyThe investigation will be carried out on subjects with Acute Coronary Syndromes.MedDRA version: 12.0Level: LLTClassification code 10049166Term: Coronary artery thrombosis prophylaxisEUCTR2008-005972-29-GBAstellas Pharma Europe B.V.1,264
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. - The RUBY-1 studyThe investigation will be carried out on subjects with Acute Coronary Syndromes.MedDRA version: 12.0Level: LLTClassification code 10049166Term: Coronary artery thrombosis prophylaxisEUCTR2008-005972-29-BEAstellas Pharma Europe B.V.1,264